Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report
Jian Wang, Bingyue Liu, Qinhong Zheng, Ruoshui Xiao, Jianxin Chen · 2024
Read Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report by Jian Wang, Bingyue Liu, Qinhong Zheng, Ruoshui Xiao, Jianxin Chen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11668661.txt.
Description
Jian Wang and co-authors report a 2024 case where a lung cancer gained a new drug target after resisting immunotherapy. The tumor had no driver changes at first and was treated with an immune checkpoint drug. When resistance developed, testing found a fresh fusion joining the CD74 gene to ROS1, a growth switch gene seen in only a small share of lung cancers. No acquired case like this had been reported before.
The patient then received a targeted drug against that fusion and achieved a partial response. The authors suggest the fusion carrying cells were a minority that grew to dominate once treatment removed their rivals. Their lesson is practical: retest tumor genetics after long immunotherapy. New targets may appear, and finding them can reopen treatment options.
Catalog record
| CREATOR | Jian Wang, Bingyue Liu, Qinhong Zheng, Ruoshui Xiao, Jianxin Chen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |